Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Acute heart failure (AHF), a common and growing health concern worldwide, is associated with high risk of post-discharge rehospitalization and mortality. Existing evidence indicates potential therapeutic benefits of serelaxin in Caucasian AHF patients, but corresponding data in Asians remain scarce. RELAX-AHF-ASIA, a multinational, randomized, double-blind, placebo-controlled, phase III trial, will evaluate the effects of serelaxin on symptom relief and clinical outcomes in Asian AHF patients, with the use of novel assessments.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Card. Fail.

Title: Journal of cardiac failure

Publisher: Elsevier BV

ISSN (Electronic): 1532-8414

ISSN (Print): 1071-9164

Publication date (Electronic): Jan 2017

Volume: 23

Issue: 1

Affiliations

[1 ] Cardiology and Intensive Care Unit, Nippon Medical School, Musashi-Kosugi Hospital, Kawasaki, Japan. Electronic address: nms-ns@nms.ac.jp.

[2 ] National Heart Centre Singapore and Duke-NUS, Singapore.

[3 ] University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, Los Angeles, California.

[4 ] Division of Cardiology, University of California, San Diego, La Jolla, California.

[5 ] Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.

[6 ] Department of Internal Medicine, Seoul National University, College of Medicine, Seoul, South Korea.

[7 ] Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

[8 ] Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

[9 ] Novartis Pharma, Basel, Switzerland.

[10 ] Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.

Article

Publisher Item ID: S1071-9164(16)31208-8

DOI: 10.1016/j.cardfail.2016.10.016

PubMed ID: 27825893

SO-VID: 86ee2817-8032-45b0-9f19-3f998904b16b

History

Keywords: Serelaxin,efficacy,acute heart failur,Asian

Data availability:

Keywords: Serelaxin, efficacy, acute heart failur, Asian

Comments

Comment on this article

scite_

Cited by 2

See all cited by